Tata Consultancy Services (TCS) on Friday launched the Advanced Drug Development (ADD) site simulation platform, which provides Biosciences companies with a single integrated platform.

The platform digitizes site selection and activation processes and facilitates data-driven decision-making when evaluating site feasibility for MultiSite clinical trials.

When planning a clinical trial, the following aspects have an impact on outcomes:

1. Selection of suitable sites for clinical trials

2. Patient population

3. The profile of the investigator

4. Treatment facilities and other parameters

However, this important activity was done manually, resulting in suboptimal site selection, which can lead to significant delays and costs.

In a statement, TCS said its website Feasibility Platform addresses this critical challenge currently faced by life-science-intensive companies, leveraging the power of digital technology to drive superior clinical outcomes.

It digitizes and automates the entire evaluation and selection process, enabling the efficient and coordinated management of hundreds of simultaneous clinical trial feasibility studies.

In addition, the platform is fully integrated with the TCS Connected Clinical Trials e-Survey platform, providing customers with a comprehensive solution for conducting field surveys and analyzing survey responses.

TCS said the leading life Sciences company is the first customer to go live with its ADD site Feasibility platform.

“We are leveraging our in-depth knowledge of the life Sciences industry to continually expand the capabilities of the TCS ADD cloud platform Suite. The site’s affordability platform will help our customers digitally transform the most important aspects of research design in their clinical trials and lead to superior results, ” said Debachis Ghosh, President, life science and health, TCS.

More